Merck's Q1 Sales Surge Past Estimates on New Drugs

Merck & Co. announced first-quarter sales figures of $16.3 billion, exceeding the analyst consensus of $15.8 billion. This performance was notably bolstered by growing demand for its innovative products.

Key drivers of this success included Winrevair, a treatment for pulmonary arterial hypertension, which generated $525 million in sales, and the newly launched injectable formulation of Keytruda, Keytruda Qlex, which brought in $128 million. These newer offerings are crucial for Merck as it navigates patent expirations for established blockbusters.

Despite some newer drugs like Ohtuvayre and Capvaxive falling short of expectations, Merck has revised its full-year outlook. The company now anticipates annual sales of at least $65.8 billion and has modestly increased its adjusted earnings forecast. This optimistic projection does not yet include the impact of the proposed acquisition of Terns Pharmaceuticals.